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CEvidence-based health care decision making requires comparison of
all relevant competing interventions. In the absence of randomized
controlled trials involving a direct comparison of all treatments of
interest, indirect treatment comparisons and network meta-analy-
sis provide useful evidence for judiciously selecting the best treat-
ment(s). Mixed treatment comparisons, a special case of network
meta-analysis, combine direct evidence and indirect evidence for
particular pairwise comparisons, thereby synthesizing a greater
share of the available evidence than traditional meta-analysis. This
report from the International Society for Pharmacoeconomics and
Outcomes Research Indirect Treatment Comparisons Good Research
Practices Task Force provides guidance on technical aspects of con-
ducting network meta-analyses (our use of this term includes most
methods that involve meta-analysis in the context of a network of O
udbu
al So
oi:10.1016/j.jval.2011.01.011vidence). We start with a discussion of strategies for developing
etworks of evidence. Next we briefly review assumptions of net-
ork meta-analysis. Then we focus on the statistical analysis of the
ata: objectives, models (fixed-effects and random-effects), frequen-
ist versus Bayesian approaches, and model validation. A checklist
ighlights key components of network meta-analysis, and substan-
ial examples illustrate indirect treatment comparisons (both fre-
uentist and Bayesian approaches) and network meta-analysis. A
urther section discusses eight key areas for future research.
eywords: Bayesian meta-analysis, direct treatment comparison, ev-
dence network, frequentist meta-analysis, heterogeneity, inconsis-
ency, indirect treatment comparison,mixed treatment comparison.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background to the task force
The International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) Board of Directors approved the forma-
tion of an Indirect Treatment Comparisons Good Research Prac-
tices Task Force to develop good research practices document(s)
for indirect treatment comparisons in January 2009. Research-
ers, experienced in systematic reviews, network meta-analysis,
synthesis of evidence, and related statistical methods, working
in academia, research organizations, the pharmaceutical indus-
try, or government, from the United States, Canada, and Europe
were invited to join the Task Force Leadership Group. Several
health care decision-makers who use indirect-direct-treat-
ment-comparison evidence in health care decisions were also
invited. The Task Force met, primarily by teleconference with
an ongoing exchange of email, and face to-face in April 2010, to
develop the topics to be addressed, agree on the outline, and
draft the report. The Leadership Group determined that, to ad-
equately address good research practices for indirect treatment
comparisons and the use of these comparisons in health care
* Address correspondence to: David C. Hoaglin, 73 Hickory Road, S
E-mail: dchoaglin@gmail.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.decisions, the Task Force Report would comprise two articles,
“Interpreting Indirect Treatment Comparisons & NetworkMeta-
Analysis for Health Care Decision-Making: Report of the ISPOR
Task Force on Indirect Treatment Comparisons Good Research
Practices: Part 1” and “Conducting Indirect-Treatment-Compar-
ison and Network-Meta-Analysis Studies: Report of the ISPOR
Task Force on Indirect Treatment Comparisons Good Research
Practices: Part 2.” Summaries were presented for comment at
the 15th Annual International Meeting in Atlanta, GA, USA, in
May 2010. Drafts were sent for comment to the Task Force Re-
view Group (103 invited and self-selected individuals interested
in this topic) in July 2010. The authors considered the com-
ments from the Task Force Review Group, and the revised
drafts were sent for comment to the ISPOR membership
(5550) in September 2010. Altogether, Part 1 received 23 com-
ments, and Part 2 received 13 comments. All written comments
are published at the ISPOR Web site. The authors considered
all comments (many of which were substantive and con-
structive), made revisions, and submitted them to Value in
Health.
ry, MA 01776, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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The ISPOR Task Force on Indirect Treatment Comparisons Good
Research Practices is publishing its report as two articles. This
article relies on Part 1 of the report [1] for motivation, concepts,
and a variety of definitions (e.g., indirect treatment comparison
[ITC], mixed treatment comparison, network meta-analysis, het-
erogeneity, similarity, and consistency).
Terminology for indirect treatment comparisons, mixed treat-
ment comparisons, and network meta-analysis varies in the liter-
ature. In practice, all of these methods involve meta-analysis in
the context of a network of evidence. Thus it seems beneficial to
use a single term for all except the simplest analyses: “network
meta-analysis” applies when the evidence network involves more
than two randomized controlled trials (RCTs) and more than two
interventions.
Part 1 of the report emphasizes aspects of network meta-anal-
ysis that are of most importance to decision makers and others
who must appreciate and apply the results of such studies. We
encourage readers to study it before proceeding with this article,
which focuses onmore-technical aspects of conducting a network
meta-analysis. The sections that follow discuss strategies for de-
veloping the network of evidence, assumptions, and statistical
methods (objectives,models, frequentist vs. Bayesian approaches,
and model validation). We then present a checklist for good re-
search practices, discuss illustrative examples, and conclude by
mentioning eight areas of current and needed research.
Identifying the evidence network
A network meta-analysis starts with a network of evidence: the
relevant treatments and the clinical trials that have compared
those treatments directly. Its structure is often readily apparent
from a diagram in which each node represents a treatment (or
perhaps a class of treatments), and each link or edge connects
treatments that have been directly compared in one ormore RCTs.
The structure of the network may have implications for the inter-
pretation of the evidence [2]. Part 1 of the report contains diagrams
for several types of evidence networks.
The literature search for a network meta-analysis builds the
network, applying the same basic standards as for ameta-analysis
leading to a direct comparison [3–6]. If the focus is a comparison of
two treatments, say B and C, the search aims to locate all studies
that have includedB and another comparator, all studies that have
included C and another comparator, and any studies that have
compared B and C directly.
If no studies have compared B and C, but each has been com-
pared with a common comparator, say A, then it may be appropri-
ate to base an indirect comparison of B and C on the direct com-
parison of B and A and the direct comparison of C and A. Beyond
this straightforward situation, B and C may have other common
comparators—or none at all.
In the absence of a common comparator for B and C, the treat-
ments with which they have been comparedmay have a common
comparator, or the connection with a common comparator may
require additional links. If more than a few links separate B and C,
an indirect comparison may be unreliable, because each addi-
tional link tends to increase the standard error of the indirect com-
parison [7]. The contribution of a link depends on a number of
factors, including the number of studies underlying that direct
comparison, the sample sizes in those studies, and the homoge-
neity of the study-specific estimates. A decision on proceeding
with an indirect comparison should, therefore, consider more in-
formation than the number of links.
It may be difficult to identify all relevant comparators for the
treatments of interest, and any search involves costs and trade-offs. It may be efficient to proceed in stages, using one of the
strategies developed by Hawkins et al. [7]. They refer to the
treatments that one wishes to compare as primary compara-
tors. Treatments that have been directly compared with a pri-
mary comparator are secondary comparators, and treatments
that have been directly compared with a secondary comparator
are tertiary comparators, and so on. The order of a comparison is
determined by the number of intermediate comparators. Thus,
first-order comparisons are direct comparisons, second-order in-
direct comparisons are based on trials that share a single interme-
diate comparator, third-order indirect comparisons involve two
intermediate comparators, and so on.
Table 1 lists the first five searches for their breadth-first strat-
egy. In the searches that exclude a comparator, one can minimize
the burden of searching by excluding the comparator that is likely
to produce the largest number of hits (e.g., placebo). Each search in
the sequence will locate, in the chosen database(s) (e.g., MEDLINE,
EMBASE), all clinical trials that contribute to an indirect compari-
son of the corresponding order: Search 1, all first-order (direct)
comparisons; Search 2, all second-order indirect comparisons;
and so on. Through these searches, additional treatments that
may not be viewed as comparators or within the scope of the
appraisal (e.g., unlicensed treatments, in some instances) may
contribute to the evidence network.
The depth-first strategy begins with the same search as the
breadth-first strategy, but it doesnot include theomittedcomparator
in any subsequent search. Search 2 targets all secondary compara-
tors identified in Search 1, Search 3 targets all tertiary comparators
identified in Search 2, and so on. Hawkins et al. [7,8] give a detailed
discussion of the searches and resulting comparisons for two sec-
ond-line treatments of advanced/metastatic non-small-cell lung
cancer.
The literature review should also search for anymeta-analyses
that have already produced direct (or even indirect) comparisons
of potentially relevant treatments, to provide empirical validation
for the analysis.
Assumptions
As discussed in Part 1 [1], network meta-analysis relies on the ran-
domization in theRCTs that compared the treatmentsdirectly. It also
involves a similarity assumption: “Combining studies should only be
considered if they are clinically and methodologically similar” [9].
Nevertheless, “no commonly accepted standard [defines] which
studies are ‘similar enough’” [9]. For network meta-analysis, covari-
ates that act as relative treatment effect modifiers must be similar
across trials (or adjusted for using meta-regression). And, when it
combines indirect evidence with direct evidence, network meta-
analysis adds the assumption of consistency: The indirect evidence
must be consistent with the direct evidence.
Ameta-analysis for a direct comparison usually requires that the
individual studies estimate either a common treatment effect or
Table 1 – The first five searches in the breadth-first
strategy. Each search uses the Boolean odds ratio to
combine comparators.
Search Comparators
1 All primary comparators except one
2 All primary comparators
3 All secondary comparators except one
4 All secondary comparators
5 All tertiary comparators except one
Adapted from Table 1 of Hawkins et al. [7].study-specific treatment effects distributed around a typical value
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fects gives rise to fixed-effects and random-effects approaches, re-
spectively. Heterogeneity among studies within a direct comparison
is acceptable, as long as their treatment effects share a common
typical value, and itmay even increase generalizability. On the other
hand, heterogeneity between the sets of studies that contribute di-
rect comparisons to an indirect comparison or a networkmeta-anal-
ysis would indicate a lack of similarity.
The discussion of models that follows uses the assumptions of
homogeneity, similarity, and consistency as needed. In practice,
onemust check these assumptions, to the extent possible. “Inves-
tigators should base decisions about combining studies on thor-
ough investigations of clinical and methodological diversity as
well as variation in effect size” [9]. Agreement is seldom perfect,
and both statistical and clinical judgment may be required (e.g.,
re-examining information in the reports on some trials, calculat-
ing direct and indirect estimates separately before proceeding to a
network meta-analysis). It may be possible to adjust for differ-
ences on study-level characteristics (via meta-regression), but
such adjustments are unlikely to overcome substantial disparities
among the studies. Interpretations of results should acknowledge
this limitation.
Statistical methods
Objectives
Objectives of networkmeta-analysismay include considering all rel-
evant evidence, answering research questions in the absence of di-
rect evidence, improving the precision of estimates by combining
direct and indirect evidence, ranking treatments, and assessing the
impact of certain components of the evidence network.
The choice of effectmeasure shouldbedeterminedby the clinical
question and the nature of the data. Common measures of relative
effect include odds ratio, risk ratio (or relative risk), mean difference,
and hazard ratio. Themodels described below apply to anymeasure
of relative effect, as long as the necessary quantities (e.g., likelihood
and link function) are properly defined.
Models
We present a sequence of models, starting with ordinary meta-
analysis by fixed effects and random effects, to show the natural
progression to fixed- and random-effectsmodels for networks and
then meta-regression models that allow treatment-by-covariate
interactions [11,12]. Somemodels for networks can accommodate
data from multiarm trials, but the presence of such trials adds
complexity to the analysis.
Themodels below relate the underlying outcome to the effects
of treatments and covariates on a scale that is appropriate for the
particular analysis (e.g., log of odds, change from baseline, or log
hazard rate). The probability distribution for the observed out-
comes (e.g., binomial, normal) would be specified separately.
Analysis based on these models could use either frequentist or
Bayesian methods; we briefly describe both.
Fixed- and random-effects meta-analysis for AB trials. Equation
1 shows the fixed-effects model for meta-analysis comparing
treatment B with treatment A.
jkj kA
j d kB
(1)
jk reflects the underlying outcome for treatment k in study j,
j represents this outcome for treatment A in study j, and d is
he effect of treatment B relative to treatment A. In a fixed-effect
nalysis, d is the same for each study. The random-effects
odel, equation 2, replaces d with j, the trial-specific effect of ireatment B relative to treatment A, and d becomes the mean of
he distribution (usually normal) of random effects, which has
ariance 2.
jkj kA
jj kB
jNd, 2
(2)
Fixed-effects network meta-analysis. When the evidence net-
work consists of multiple pairwise comparisons (i.e., AB trials, AC
trials, BC trials, and so on), the set of comparators usually varies
among studies, complicating the notation. One approach labels
the treatments A, B, C, and so on, and uses A for the primary
reference treatment in the analysis. In each study it designates
one treatment, b, as the base treatment. The labels can be assigned
to treatments in the network in such a way that the base treat-
ments follow A (i.e., B, C, and so on) and the non-base treatments
follow all the base treatments in the alphabet. In the variousmod-
els, “after” refers to this alphabetical ordering. The general fixed-
effects model for network meta-analysis can be specified as fol-
lows:
jkjb bA,B, C,
jb dbkjb dAk dAb kB,C,D,
if k b
if k is ' after' b
dAA 0
(3)
jb is the outcome for treatment b in study j, and dbk is the fixed
effect of treatment k relative to treatment b. The dbk are identified
y expressing them in terms of effects relative to treatment A:
bk  dAk  dAb with dAA  0 (the order of the subscripts on dbk is
conventional, but counterintuitive). For the underlying effects,
this relation is a statement of consistency: the “direct” effect dbk
and the “indirect” effect dAk  dAb are equal.
In the simplest indirect treatment comparison, A is the pri-
mary reference treatment and also the base treatment for the AB
trials and the AC trials. The term “adjusted indirect comparison”
has been applied to such analyses, but it is an infelicitous choice,
because the comparison involves no adjustment in any of the
usual senses. We prefer “anchored indirect comparison”; the indi-
rect comparison of B and C is anchored on A.
Random-effects network meta-analysis. As above, the random-
ffects model replaces dbk with jbk, the trial-specific effect of treat-
ent k relative to treatment b. These trial-specific effects are drawn
rom a random-effects distribution: jbk Ndbk, 2. Again, the dbk are
identified by expressing them in terms of the primary reference
treatment, A. Thismodel assumes the same random-effect variance
2 forall treatmentcomparisons, but theconstraint canbe relaxed. (A
fixed-effects model results if 2 0.)
njkjb bA,B, C ,
jbjbk kB,C,D,
if k b
if k is ' after ' b
jbkN(dbk, 2)N(dAk dAb, 2)
dAA 0
(4)
Meta-regression models with treatment-by-covariate interactions.
Meta-regression models include study-level covariates and pro-
vide a way to evaluate the extent to which covariates account for
heterogeneity of treatment effects. They can also reduce bias and
inconsistency between treatment comparisons when covariates
are distributed unevenly [13,14]. The covariates enter the model
via the mean of the distribution of random effects. The model
below uses study-level values of a single covariate, X , and allowsj
ts coefficient, bk, to vary among the comparisons [12]. It is a good
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432 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 2 9 – 4 3 7idea to center a covariate (e.g., at its overall mean), to make the
results more interpretable.
njkjb bA,B, C,
jbjbk kB,C,D,
if k b
if k is ' after ' b
jbkNdbkbkXj,2NdAk dAb AkAbXj,2
dAA 0,AA 0
(5)
Other models can use values of the covariate for the combina-
tion of study and treatment. A simplification of the model above
uses the same coefficient for all comparisons:
njkjb bA,B, C,
jbjbk kB,C,D,
if k  b
if k is ' after' b
jbkN(dbkXj, 2)N(dAk dAbXj, 2) if bAN(dbk, 2)N(dAk dAb, 2) if b	A
dAA 0
(6)
If a model with a constant  is satisfactory, comparisons
mong treatments (adjusted for the contribution of the covariate)
re straightforward, because dAk  dAb applies at any value of the
ovariate (study-level or study-by-treatment-level). In the model
ith bk the adjustment for the covariate can improve internal
validity, but the analystmust choose a value ofX at which tomake
comparisons among treatments. Meta-regression also has the
drawback that the relation between the outcomeand the covariate
in patient-level data can differ, and even be opposite in direction,
from the corresponding relation in study-level summaries.
If the network appropriately includes amultiarm trial, omitting it
from the analysis may introduce bias. The analysis, then, must take
into account the correlation among the effect estimates for the pairs
of arms; some methods can do this more easily than others. It is
incorrect to analyze the pairwise effects in amultiarm trial as if they
came from separate studies. This error is not rare; an example in a
CanadianAgency forDrugs andTechnologies inHealth report shows
the input data for the threedirect comparisons in a three-arm trial as
three separate studies [15]. Salanti et al. [16] illustrate analyses that
incorporate correlation among arms.
Analysis framework: Frequentist versus Bayesian
approaches
Frequentist approach. The label “frequentist” applies to most of
the traditional statistical methods applied in making compari-
sons, including the weighted means with confidence intervals
(based on an assumed normal distribution) in fixed-effects and
random-effects meta-analysis and the Mantel-Haenszel estimate
(e.g., for an odds ratio) (a fixed-effects procedure). In models such
as network meta-analysis and meta-regression, estimation and
inference are based on some form of maximum likelihood.
Bayesian approach. Bayesian methods combine the likelihood
(roughly, the probability of the data as a function of the parameters)
with a prior probability distribution (which reflects prior belief about
possible values of those parameters) to obtain a posterior probability
distribution of the parameters [17]. The posterior probabilities pro-
vide a straightforward way tomake predictions, and the prior distri-
bution can incorporate various sources of uncertainty. For parame-
ters such as treatment effects, the customary prior distributions are
noninformative. The assumption that, before seeing the data, all val-
uesof theparameterareequally likelyminimizes the influenceof the
prior distribution on the posterior results. When information on the
parameter is available (e.g., fromobservational studies or fromapre-
vious analysis), however, the prior distribution provides a natural
way to incorporate it. bFor one random-effectsnetworkmodel inwhich theoutcomemea-
sure is log odds, the Bayesian analysis has the following components:
likelihood:
rjk binomialpjk, njk
model:
logitpjkjb bA,B, C,
jbjbk kB,C,D,
if k b
if k is ' after ' b
jbk  Ndbk,2NdAk dAb,2
dAA 0
priors:
dAknormal0, 106 kB,C,D
uniform0, 2
(7)
In the likelihood the observed number of events for treatment
k in study j, rjk, has a binomial distribution (independent of other
reatments in study j and of other studies) whose event probability
is pjk, described by the model. The parameters in the distributions
of random effects have vague prior distributions: N(0, 106) for the
dAk (independently) and Uniform(0, 2) for . These priors are com-
mon choices in such models.
Differences. Formost of themodels ananalysis could followeither a
requentist approach or a Bayesian approach. In current practice
ost meta-analyses for direct comparisons use frequentist meth-
ds. For themore-complicatedmodels, particularly networks involv-
ng mixed treatment comparisons, Bayesian methods have under-
one substantially greater development, facilitated by advances in
omputing that support their computational intensity and the need
omonitor convergence to the posterior distribution. Lumley [18] de-
cribed amaximum-likelihood approach using linearmixedmodels;
is method has been applied in relatively few articles [19–21].
In brief, a frequentist analysis yields point estimates and con-
dence intervals. The typical Bayesian analysis produces an em-
irical version of the joint posterior distribution of the parameters,
rom which one can derive summary measures for individual pa-
ameters, such as the posteriormean and a “credible interval” (CrI)
e.g., the endpoints of the 95%CrI are the 2.5 and 97.5 percentiles of
he posterior distribution), as well as posterior distributions for
unctions of parameters (e.g., estimates of the probability that
ach treatment is best). The Bayesian CrIs reflect the uncertainty
n estimating heterogeneity, whereas frequentist random-effects
odels do not propagate that uncertainty.
Choices of prior distributions are, to some extent, arbitrary, so
hey are often subjected to sensitivity analysis, which may be espe-
ially important for priors on heterogeneity in random-effects mod-
ls. Lambert et al. [22] discuss sensitivity analysis for exploring the
ffect of the use of vague priors. On the other hand, some frequentist
ethods involve approximations and assumptions that are not
tated explicitly or verifiedwhen themethods are applied. Therefore
oth insight into the sensitivity of results fromaBayesian analysis to
ssumptionsonpriors and transparent reportingof assumptionsun-
erlying a frequentist analysis are highly important.
Model validation
Evaluation of assumptions. Asmentioned above, assumptions re-
uire checking. In assessing similarity, researchers may be able to
se statistical information, but they must rely primarily on clinical
udgment ofwhether differences among studiesmay affect the com-
arisons of treatments or make some comparisons inappropriate.
Evaluation of homogeneity and consistency (if the network
upports both direct and indirect comparisons) should be speci-
ed as components of the analysis and should reflect the risks and
enefits of combining data for the particular research question.
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433V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 2 9 – 4 3 7The discussion that follows sketches the current state of some
approaches for examining homogeneity and consistency.
Ordinary meta-analyses (especially by frequentist methods)
customarily evaluate heterogeneity of effects, as a basis for choos-
ing between a fixed-effect or a random-effects procedure. Boren-
stein et al. [23] advise against considering a fixed-effectmodel as a
presumptive choice; they explain that fixed-effect models and
random-effects models reflect fundamentally different assump-
tions about the distribution of the data. Thus, the choice should
reflect an understanding of whether the studies share a common
effect and the goals of the analysis. These issues are at least as
important in a network meta-analysis. When information on het-
erogeneity within the direct comparisons is available, consideration
of it can formapreliminary step in a networkmeta-analysis, but one
should first examine potential effect modifiers, because disparities
among studies may preclude analysis of the network. The common
measures of heterogeneity in a direct comparison use the studies’
estimates, yi (i  1, . . . , k), of effect and the estimated variances of
hose effect estimates, si
2, to form the weighted mean, yw  wiyi⁄
wi, wherewi 1 ⁄ si2 yw is the fixed-effect estimate of the common
ffect). They then calculate the statistic Q,
wiyi yw2
and either refer it to the chi-squared distribution on k – 1 degrees
f freedom or quantify the heterogeneity in terms of the measure
2  [Q – (k – 1)]/Q [24]. I2 (usually expressed as a percentage) esti-
ates the proportion of total variation among the effect estimates
hat is due to heterogeneity: I2 30% is considered mild heteroge-
eity, and I2 50%, notable heterogeneity. Deeks et al. [25] discuss
trategies for addressing heterogeneity. It is important to examine
he effects graphically for the presence of groups and outliers;
hese numerical measures or tests should have only a secondary
ole [9,26]. It has long been known that the large-sample approxi-
ation for the distribution of Q is not accurate for moderate sam-
le sizes; thus, use of Q for testing homogeneity should be aban-
oned in favor of more-accurate tests [27].
A departure from consistency arises when the direct and indi-
ect estimates of an effect differ (e.g., the direct estimate of dBC
does not equal the indirect estimate obtained from dAC – dAB). The
treatments involved (and their comparisons)must belong to a loop
in the network of evidence. Thus, consistency is a property of
loops, rather than of individual comparisons. Researchers must
evaluate departures from consistency and determine how to in-
terpret them. Salanti et al. [16] provide much valuable guidance.
Most agencies to which the results of a network meta-analysis
could be submitted currently require that direct estimates and
indirect estimates be calculated separately and shown to be con-
sistent before direct evidence and indirect evidence are combined.
Methods for evaluating consistency have been an active area of re-
search. In a network containing a single loop (and no multiarm trials)
Bucher et al. [28] compared the indirect estimate of a treatment effect
with the corresponding direct estimate (the resulting test of consis-
tency, however, has shortcomings that may make it unreliable). For
networksof two-armtrials that contain loops, Lumley [18] introduceda
frequentist model that uses one variance parameter to summarize in-
consistency in thenetwork as awhole. Lu andAdes [13] focused on the
structure of networks and expanded a hierarchical Bayesianmodel by
adding one parameter for each independent consistency relation. By
comparing the models with and without those parameters, one can
assess overall inconsistency, and the posterior distributions of the
added parameters show the extent of inconsistency in the various
loops. A graphical assessment canuse the forest plot of LamandOwen
[29] to examine consistency betweendirect and indirect estimates. In a
hierarchical Bayesian setting, Dias et al. [30] extended the approach of
Bucher et al. [28] to general networks (but not using indirect evidence
from multiarm trials), by deriving a weighted difference between the
estimate fromthenetworkand thedirect estimate. Byplotting thepos-teriordensitiesof thedirect, indirect,andnetworkestimates, theyshow
how the direct evidence and the indirect evidence are combined in the
networkestimate.Foreacheffect thathasdirectevidenceDiasetal. [30]
also split the information into direct and indirect information and ex-
amine theposterior distributionof thedifferencebetween the resulting
direct and indirect estimates. They discuss how to handle multiarm
trials in this analysis.
Assessment of model fit. In frequentist analyses, measures of
model fit are similar to those for direct evidence anddepend on the
particular outcome measure. Bayesian analyses customarily use
deviance (a likelihood-basedmeasure)—the lower the residual de-
viance, the better the fit. For comparing models, the deviance in-
formation criterion (DIC) adds a penalty term, equal to the effec-
tive number of parameters in themodel [31]. If a model fits poorly,
graphical techniques can aid more-detailed examination.
Sensitivity analysis. Sensitivity analyses should focus on the ar-
eas of greatest uncertainty. Potential effect modifiers can be ex-
plored by stratifying on variations in study design or population.
Comparisons between random-effects and fixed-effects analyses
may be appropriate. Bayesian analyses should also explore the
influence of choosing different prior distributions.
Checklist for good research practices
Practices for conducting and reporting systematic reviews and
meta-analyses have received extensive discussion since the mid-
1980s and have been the subject of guidelines and recommenda-
tions, most recently the PRISMA statement [6]. Because network-
meta-analysis studies have many features in common with
systematic reviews and meta-analyses, we recommend that they
follow all applicable parts of the PRISMA checklist. In addition,
Table 2 supplements the checklist in Part 1 [1] by highlighting key
components of network-meta-analysis studies, areas in which
they have distinct (often additional) requirements, and recent de-
velopments. We intend this checklist for use in light of ongoing,
dynamic research on network meta-analysis. Improved methods
and their application will lead to changes in the checklist.
Illustrative examples
Separate analyses of a portion of the data from two extensive
meta-analyses provide illustrations of ITC (both frequentist and
Bayesian approaches) and network meta-analysis. This section
also discusses available software.
Stettler et al. [32] reported on a collaborative networkmeta-anal-
ysis of outcomes associated with two drug-eluting stents (the pacli-
taxel-eluting stent [PES] and the sirolimus-eluting stent [SES]) and
bare-metal stents (BMS). The literature search yielded 7 RCTs com-
paring PES with BMS, 15 RCTs comparing SES with BMS, 14 RCTs
comparing SES with PES, and 1 RCT comparing all three.
Their analysis of overall mortality and other primary safety
endpoints is an instructive application of Bayesian random-effects
models for network meta-analysis involving multiple follow-up
times [33]. This example focuses on the rate, at 1 year, of target
lesion revascularization (TLR), a secondary effectiveness endpoint
involving subsequent percutaneous intervention.
The Appendix for this article (found at doi:10.1016/j.jval.
2011.01.011) gives the details of the Bayesian analysis of target
lesion revascularization on the log-odds scale: direct meta-analy-
ses of PES versus BMS, SES versus BMS, and PES versus SES; the
corresponding separate indirect comparisons; the comparisons
from the networkmeta-analysis; andWinBUGS code and the data.
The forest plot in Figure 1 shows the data from the studies that
compared PES and SES, the study-specific odds ratios for PES ver-
m
a
a
c
in th
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overall odds ratio: traditional fixed-effects pairwise (using the
Mantel-Haenszel method), traditional random-effects pairwise
(using the DerSimonian-Laird method), Bayesian direct, Bayesian
indirect, and Bayesian network (Fig. 3 of the Appendix, found at
doi:10.1016/j.jval.2011.01.011, shows odds ratios for SES versus
PES). To facilitate numerical comparisons, Table 3 presents the esti-
ates. The traditional fixed-effects and random-effects estimates
nd their 95% confidence intervals differ very little: 1.39 (1.17 to 1.66)
nd 1.38 (1.16 to 1.65). The random-effects interval is no wider, be-
ause the estimated heterogeneity is small (I2 0.74%).
Tomake an anchored indirect estimate of the odds ratio for PES
versus SES, using the direct estimates for PES versus BMS and SES
versus BMS, it is necessary to omit the three-arm trial (or do a
more-complicated calculation that recognizes the contributions of
that trial to both direct estimates). The right-hand columnof Table
3 gives the estimateswithout the three-arm trial. The fixed-effects
and random-effects indirect estimates are similar, 1.74 (1.28 to
2.36) and 1.70 (1.09 to 2.65) and are considerably higher than their
direct counterparts. The confidence interval for the random-ef-
fects indirect estimate is considerably wider than that for the
fixed-effects estimate, and both are substantiallywider than those
for the direct estimates. All the confidence intervals are wide
enough that further analysis would be required to assess consis-
tency between the indirect estimates and direct estimates.
The three Bayesian estimates, 1.55 (1.17 to 2.05), 1.60 (0.98 to
2.47), and 1.55 (1.22 to 1.96), are similar, and somewhat higher than
the traditional fixed-effects and random-effects estimates. The
indirect estimate has the widest credible interval. More impor-
tantly, the estimate from the Bayesian networkmeta-analysis has
a somewhat narrower credible interval than the Bayesian direct
estimate, as a consequence of taking into account all the evidence
in the network. We would report that estimate, 1.55 (1.22 to 1.96),
as the odds ratio for PES versus SES.
To provide a richer illustration of some aspects of network
meta-analysis (e.g., correlations between estimates and probabil-
ity of a treatment’s being best), the Appendix (found at doi:
10.1016/j.jval.2011.01.011) also analyzes data from a network of
112 RCTs that compared (in the aggregate) the acceptability of 12
new-generation antidepressants in the acute-phase treatment of
Table 2 – Checklist of good research practices for conductin
Checklist item
Search strategies ● Follow conventional guidelines
literature, and time frames, and
● Consider iterative search metho
the initial search focusing on lo
Data collection ● Set forth evidence network dem
identified study reports
● Follow conventional guidelines
● Include sufficient study detail in
homogeneity (e.g., patient and
Statistical analysis plan ● Prepare statistical analysis plan
necessary
● Provide step-by-step descriptio
procedures for checking them
● Describe analytic features speci
synthesis, sensitivity analysis, s
Data analysis ● Follow conventional guidelines
● Evaluate violations of similarity
● If similarity or consistency is a
covariate interactions to reduce
Reporting ● Follow PRISMA statement for re
● Explicitly state the study resear
● Provide graphical depiction of e
● Indicate software package usedunipolar major depression [34].Software
We used WinBUGS for the Bayesian analyses in this example [35].
Other software for Bayesian analysis includesOpenBUGS [36]. Ver-
sion 9.2 of SAS [37] includes a procedure for Markov chain Monte
Carlo, but the examples in the documentation appear not to in-
clude applications in meta-analysis. Frequentist approaches have
been developed by Lumley [18] in R using linearmixedmodels and
are also feasible in SAS using PROC NLMIXED [38].
Areas for future research
Research has produced a substantial body ofmethods for network
meta-analysis, but a number of topics would benefit from further
investigation. This section discusses eight of them, roughly in or-
der of priority.
Adjustments to improve the similarity of trials and empirical
assessment of their benefit
Patients studied in the various trialsmay not be comparable. If these
differences among trials are treatment-effect modifiers, an ITC is
biased [39]. In addition, in a networkmeta-analysis different types of
comparisons may be inconsistent [12]. Because the number of stud-
ies is often limited, adjustment by incorporating covariates with
“conventional” meta-regression approaches may be unsatisfactory
[38–40]. In addition, limited or inconsistent reporting of the study-
level covariates (or effects for levels of a possible effect modifier)
complicates analysis. Future studies should examine the value of
existing methods to enhance comparability of trials, as well as the
level of consistency in reporting of study-level covariates.
Structure and properties of networks
To explore the geometry of treatment networks for four ormore inter-
ventions, Salanti et al. [2] used twomeasures from the ecological litera-
ture,diversityandco-occurrence.Diversitycharacterizes thenumberof
interventions and, for a set of networkswith the samenumberof inter-
ventions, the frequency distribution of interventions. Co-occurrence
measurestheappearanceofspecificpairwisecombinationsof interven-
tions. These measures allow 1) comparing networks of different sizes
within a particular network shape and 2) signaling the presence of po-
d reporting network-meta-analysis studies.
Recommendation(s)
stematic literature searches; be explicit about search terms,
d use of ad hoc data
identify higher-order indirect comparisons that do not come up in
rder indirect comparisons
rating direct and indirect linkages between treatments, based on
ata collection; use a pre-specified protocol and data extraction form
extraction to permit assessment of comparability and
characteristics, comparators, and outcome measures)
r to data analysis, but permit modifications during data analysis, if
all analyses, including explicit statements of all assumptions and
network meta-analysis, including comparability and homogeneity,
oup analysis and meta-regression, and special types of outcomes
atistical model diagnostics
nsistency assumption in evidence network
em, consider use of meta-regression models with treatment 
ng of meta-analysis
estions (e.g., in Introduction or Objectives section of report)
ce network
e analysis and provide code (at least in an online appendix)g an
for sy
avoi
ds to
wer-o
onst
for d
data
study
prio
ns of
fic to
ubgr
for st
or co
probl
bias
porti
ch qu
videntential biases in the assessment or reporting of specific comparisons. It
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terize evidence networks, or how they correlate with effect estimates,
heterogeneity, similarity, or consistency.
Methods for verifying the assumption of consistency
As discussed above, a number of approaches, including graphical
representations, have been developed to assess consistency in net-
work meta-analysis. Salanti et al. [16] and Dias et al. [30] have dis-
cussed the strengths and weaknesses of these approaches. Further
research is needed, to improve understanding of thesemethods and
encourage their use. As Salanti et al. [16] point out, a measure for
inconsistency analogous to I2 would be a welcome addition.
Multiple outcomes
Meta-analyses that consider multiple outcomes usually do so in
separate analyses. Intuitively, however, because “multiple end-
points are usually correlated, a simultaneous analysis that
Fig. 1 – Forest plot for the PES vs. SES comparison, showing
scale, the fixed-effects pairwise (Mantel-Haenszel) and rand
results from the Bayesian network meta-analysis of direct, itakes their correlation into account should add efficiency andaccuracy” [41]. Though this approach has received considerable
attention in recent years [42–44], it has not yet been extended to
network meta-analysis for studies that have analyzed multiple
endpoints [45].
Lu et al. [33] illustrated how to combine data recorded at mul-
tiple time points; these methods can be extended to estimate
treatment effects at multiple time points using the network for
each time point and the correlation between multiple observa-
tions. This would be beneficial to cost-effectivenessmodels where
transition probabilities vary over time.
Historically meta-analysts have combined studies using a com-
mon summarymeasure (e.g., mean change from baseline) and have
excluded studies that presented the same measure in a slightly dif-
ferentway (e.g.,meandifference).Methods for combiningalternative
summary measures have recently been proposed in order to mini-
mizepotential selectionor reportingbias:Weltonet al. [46] presented
methods for combining mean change from baseline and mean dif-
ata from the individual studies and, on the odds-ratio
ffects pairwise (DerSimonian-Laird) estimates and the
ect, and combined evidence.the d
om-e
ndirference data from different studies, and Woods et al. [47] presented
436 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 2 9 – 4 3 7methods for combining binarymortality data with hazard ratio data
from different studies in a single analysis.
Such approaches embrace more studies than separate analyses
for each summary measure and also maximize network connectiv-
ity. Health technology assessment bodies such as the National Insti-
tute for Health and Clinical Excellence may view the use of a single
summary measure (and thereby exclusion of certain studies) as po-
tential selection bias and insist on including various summarymea-
sures of the same endpoint within a single analysis where these are
available [46–48]. Further exploratory work is needed on combining
different summary measures of the same endpoint.
How to handle heterogeneity with small numbers of studies
per intervention?
Many networkmeta-analyses involve too few studies to employ either
random effects [8] ormeta-regression [12]. The resulting overspecifica-
tion(i.e., thenumberofparameterstobeestimatedexceedsthenumber
of studies) can compel the meta-analyst to use a fixed-effects model
when heterogeneity may be present. Cooper et al. [12] proposed alter-
native random-effectsmodels incorporating covariate adjustment that
can mitigate overspecification, depending on the distribution of inter-
actions. In the Bayesian framework, use of informative prior distribu-
tions for the heterogeneity parameter would offer a compromise be-
tween fixed-effects and random-effects models. These methods need
to be further explored.
Size of the network: evidence space versus decision space
Thepractitionermayask, “Is thereadirectwayofdecidingonthesizeof
anetwork? Is there anoptimum?What size is sufficient?” Size involves
both the number of studies and the number of treatments. If the num-
ber of studies is too small, an analysis cannot use random effects or
meta-regression.However, includingtoomanystudiescan increasethe
level of inconsistency, potentially resulting in confounding bias. On the
otherhand, anestablished treatmentmayhavebeen included inmany
studies. The size of thenetworkdependson the therapyand treatment
contrast [33], comparators, uncertainty, sample size, homogeneity,
quality of information, and exact patient population [39]. Also, it seems
Table 3 – Estimates (with 95% confidence interval or
credible interval) of the odds ratio for PES vs. SES on
target lesion revascularization at 1 y, using data that
include and exclude the three-arm trial (BASKET).
Approach All trials Omitting three-arm
trial
Fixed-effects pairwise
(Mantel-Haenszel)
1.39 (1.17 to 1.66) 1.45 (1.21 to 1.74)
Random-effects
pairwise
(DerSimonian-
Laird)
1.38 (1.16 to 1.65) 1.43 (1.19 to 1.73)
Bayesian direct 1.55 (1.17 to 2.05) 1.51 (1.16 to 1.97)
Bayesian indirect 1.60 (0.98 to 2.47) 1.80 (1.14 to 2.73)
Bayesian network
meta-analysis
1.55 (1.22 to 1.96) 1.57 (1.26 to 1.96)
Fixed-effects anchored
indirect
1.74 (1.28 to 2.36)
PES vs. BMS 0.40 (0.32 to 0.49)
SES vs. BMS 0.23 (0.18 to 0.28)
Random-effects
anchored indirect
1.70 (1.09 to 2.65)
PES vs. BMS 0.39 (0.28 to 0.54)
SES vs. BMS 0.23 (0.17 to 0.31)
BMS, bare-metal stent; PES, paclitaxel-eluting stent; SES, sirolimus-
eluting stent.that thenetworksizeshoulddependontheexpected levelofconfound- ving. Though methods can account for inconsistency, and sensitivity
analysis can evaluate the robustness of the outcomes derived from a
particular network, many issues remain in defining the best network
anddecidingonthesizeofthenetwork. Includingall relevantdatamust
be balanced against minimizing inconsistency and heterogeneity
among studies and populations. Improvements in transparency in the
development of networks and in the use of network meta-analysis
would help nonspecialists (e.g., health care decision makers) under-
stand thestudyprocess,methodology, andfindings [39,49]. Suttonetal.
[49] suggested that guidance for developing a robust network could be
based on expert clinical opinion or statistical/economic considerations
of efficiency or cost-effectiveness regarding gains from expanding the
network. These issues require further elaboration and possibly a set of
standardized criteria.
Individual patient data in network meta-analysis
Meta-analyses of individual patient data (IPD) are considered the gold
standard, as they provide the opportunity to explore differences in ef-
fects among subgroups [50,51]. Similarly, networkmeta-analysis based
onIPDcanbeconsideredsuperior.WhenIPDareavailable,meta-regres-
sion models usually have sufficient power to evaluate heterogeneity
and improve consistency. Apart from potentially questionable fit, ad-
justments based on aggregate-level covariates can produce ecological
bias [52]. This problem can be avoided by using IPD, or minimized by
using IPD for a subset of studies [53]. The added value of using IPD in
networkmeta-analysis should be further evaluated to develop recom-
mendations on its relevance and practicability.
Further development of frequentist methods
For network meta-analysis in some more-complex networks of evi-
dence, especially those involving multiarm trials, frequentist methods
are lesswelldevelopedandaccessiblethantheirBayesiancounterparts.
Furtherdevelopmentwouldbenefituserswhoprefer frequentistmeth-
ods. Potential approaches include confidence distributions and score-
based confidence intervals [54,55]. Also, several widely used methods
formeta-analysis relyonapproximationsorassumptions.Forexample,
the fixed-effect estimate and random-effects estimate of treatment ef-
fect (weighted means) assume that the weights based on estimated
variancesofstudy-leveleffectsarecloseenoughtotheweightsbasedon
true variances, and that the estimated variances are uncorrelatedwith
theestimatedeffects.Thefixed-effect andrandom-effectsmethodsare
often unsatisfactory, especially when the sample sizes of some of the
individual studies aremodest [56–59]. A thorough review of the empir-
ical evidence is needed.
Conclusion
This article, the second part of the report from the Task Force, sets
out general best-practice guidelines for practitioners who are in-
terested in performing networkmeta-analyses. The underpinning
statisticalmethods are presented and supported by examples that
suggest ways of presenting results to nonspecialized audiences.
The techniques are not always applicable and may be subject to
the biases and limitations discussed in this report. Failure of the
assumptions of similarity and consistency may render results
questionable. Where the techniques are applicable, care and trans-
parency should be employed, and we encourage adherence to our
checklist. Standardization of methods would enhance the overall
credibility and applicability of indirect treatment comparisons and
network meta-analysis. Finally, ongoing research in many areas
should lead to periodic revisions of the recommendations.
Supplemental Material
Supplemental material accompanying this article can be found in the
online version as a hyperlink at doi:10.1016/j.jval.2011.01.011 at www.
alueinhealthjournal.com/issues (select volume, issue, and article).
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